person
as of 2026-07-01Joshua T Kantrowitz, MD
Joshua Kantrowitz, MD
ORCID 0000-0003-1127-7016
at a glance
Roles: Principal Investigator, Author
KOL signal score 16
6 publications · 0 high-value
Cross-drug reach: 5 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Nathan Kline Institute
Roles
Principal Investigator, Author
KOL signal
16
Publications
6 (0 high-value)
Trial investigator
yes
Publishes on
5 drugs
Trials led
4
D-serine and Cognitive Remediation in Schizophrenia
NCT02156908Phase 2Completed
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
NCT07423546Phase 1, Phase 2Not Yet Recruiting
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
NCT01474395Phase 2Unknown
Conversion to Antipsychotic Monotherapy
NCT01368458—Terminated
Publications & congress
5
Serotonin type 3 receptor (5-HT
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
CNS drugs · 2025
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.
CNS drugs · 2021
Targeting Serotonin 5-HT
CNS drugs · 2020
The Potential Role of Lumateperone-Something Borrowed? Something New?
JAMA psychiatry · 2020
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on